Precision Biosciences (DTIL) Capital Expenditures (2018 - 2026)
Precision Biosciences' (DTIL) quarterly Capital Expenditures came in at $18000.0 in Q1 2026, down 71.88% year-on-year from $64000.0 in Q1 2025, and down 5.26% on a QoQ basis from $19000.0 in Q4 2025.
Precision Biosciences (DTIL) Capital Expenditures (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has 9 years of Capital Expenditures data on file, last reported at $18000.0 in Q1 2026.
- On a quarterly basis, Capital Expenditures fell 71.88% year-over-year to $18000.0 in Q1 2026; TTM through Mar 2026 was $39000.0, a 82.89% decrease from a year earlier, with the FY2025 full-year figure at $85000.0, down 66.0% from the prior year.
- Capital Expenditures for Q1 2026 stood at $18000.0, down from $19000.0 in the prior quarter.
- Over the last five years, Capital Expenditures for DTIL reached as high as $1.1 million in Q3 2022 and fell as low as -$26000.0 in Q4 2023.
- Historically, Capital Expenditures has averaged $351812.5 across 5 years, with a median of $91500.0 in 2024.
- Across the five-year window, Capital Expenditures sank 104.11% in 2023 and soared 473.08% in 2024, its largest moves.
- Year by year, Capital Expenditures stood at $632000.0 in 2022, then slumped by 104.11% to -$26000.0 in 2023, then surged by 473.08% to $97000.0 in 2024, then sank by 80.41% to $19000.0 in 2025, then dropped by 5.26% to $18000.0 in 2026.
- Per Business Quant data, the three most recent Capital Expenditures figures were $18000.0 in Q1 2026, $19000.0 in Q4 2025, and $2000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 786,000.00 |
| 10 | Precision Biosciences | 178.85 Mn | 150.56 Mn | - | 18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18,000.00 |
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | 19,000.00 |
| Dec 31, 2025 | 19,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 64,000.00 |
| Mar 31, 2025 | 64,000.00 |
| Dec 31, 2024 | 97,000.00 |
| Dec 31, 2024 | 97,000.00 |
| Sep 30, 2024 | 39,000.00 |
| Sep 30, 2024 | 39,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Mar 31, 2024 | 86,000.00 |
| Mar 31, 2024 | 86,000.00 |
| Dec 31, 2023 | -26,000.00 |
| Dec 31, 2023 | -26,000.00 |
| Sep 30, 2023 | 386,000.00 |
| Sep 30, 2023 | 386,000.00 |